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Introduction 28 
Chronic Pseudomonas aeruginosa lung infections commonly occur in patients suffering from 29 
bronchiectasis, leading to increased morbidity and mortality (1-4). Severe bronchiectasis 30 
often affects patients beyond the age where lung transplantation is indicated resulting in a 31 
high mortality rate (5). 32 
Recently, we identified that ~20% of patients with bronchiectasis and chronic P. aeruginosa 33 
infection had excess IgG2 specific to the bacterial O-antigen (6). In contrast to the serum 34 
bactericidal effect normally associated with antibody, this IgG2 inhibited immune killing of 35 
the infecting strain (6). Crucially, patients with inhibitory antibody had worse lung disease 36 
(6).  37 
We hypothesised that removal of inhibitory antibody might restore host immune killing and 38 
improve patient health. Plasmapheresis is typically used to treat conditions where injurious 39 
auto-antibodies arise (7, 8). Here we used plasmapheresis to remove inhibitory IgG2 from the 40 
serum of two critically ill patients with chronic P. aeruginosa infections (6).  41 
Results 42 
PN1 was a 64-year-old male diagnosed with bronchiectasis aged fifteen, after measles and 43 
pneumonia. P. aeruginosa was first detected in 2002. Increased morbidity was observed from 44 
2011 when significant multilobar changes were observed. PN1 entered respiratory failure in 45 
2012. He was unfit for a lung transplant due to unrelated renal problems. PN3 was a 69-year-46 
old female had chronic multi-drug resistant P. aeruginosa infection since their childhood 47 
onset of bronchiectasis (pink disease). PN3 deteriorated rapidly in 2014 and entered 48 
respiratory failure.  49 
Both patients were housebound, required long-term oxygen and nocturnal ventilation, and 50 
their disease was progressively refractory to treatment. Both failed to respond to multiple 51 
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courses of alternating broad spectrum antibiotics guided by sensitivity testing, including 14-52 
21 day courses of IV piperacillin/tazobactam, meropenem and ceftazidime. At time of 53 
plasmapheresis, PN1 and PN3 had a FEV1% predicted of 19.8 and 27.9 respectively. 54 
Previously, we demonstrated these patients’ sera possessed inhibitory antibodies against our 55 
prototypical P. aeruginosa (6). Herein we determined both had impaired serum killing of 56 
their cognate P. aeruginosa, even when serum was mixed 50:50 with healthy-control serum 57 
(HCS), indicating the presence of inhibitory antibodies (Figure 1A). Complete killing was 58 
only restored when HCS represented >70% and >90% of the mixed sera, respectively (not 59 
shown). Both strains expressed high levels of O-antigen and patient sera had high IgG2 titers 60 
specific to their O-antigen serotype (Figure 2B).  61 
We hypothesised that removing inhibitory antibody would ameliorate disease. Upon 62 
discussion with the hospital approvals board, in light of patient decline, and after patient 63 
consent, we conducted plasmapheresis as salvage therapy. Treatment was conducted for four 64 
hours daily for five days, with albumin and electrolyte replacement. Commercial intravenous 65 
pooled immunoglobulin (IVIg; Privigen®) was administered (0.4 g/kg body weight) for five 66 
days after plasmapheresis ended. Privigen did not inhibit serum-mediated killing of P. 67 
aeruginosa, nor did it confer on patient serum bactericidal activity. 68 
After treatment, both patients were discharged home. Within two weeks both were no longer 69 
housebound, although PN3 still required oxygen. Days in hospital and i.v. antibiotic use 70 
dropped significantly (P<0.01) for both patients (Figure 1B, 2A). A significant (P<0.001) and 71 
sustained decrease in the inflammatory marker CRP was observed (Figure 1B). Sputa were P. 72 
aeruginosa negative for up to three months post-plasmapheresis, despite being cultured from 73 
over 90% of sputum samples in the previous 18 months (Figure 2B). The FEV1% predicted 74 
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for PN1 did not improve significantly in the year post treatment. In contrast, PN3’s FEV1% 75 
predicted improved significantly (P<0.001) from 27.9% in the year pre-treatment to 37.8% 76 
Anti-LPS IgG2 titres dropped significantly with plasmapheresis but increased over 90 days so 77 
that sera were unable to kill the cognate P. aeruginosa (Figure 2B). Re-emergence of 78 
inhibition correlated with the reappearance of P. aeruginosa in sputa, increased 79 
symptomatology and poorer responses to subsequent antibiotic courses. This prompted a 80 
second round of plasmapheresis for PN1. As before, the patient improved clinically (Figure 81 
2), although again post treatment, titres of IgG2 eventually increased to a point where they 82 
inhibited serum-mediated killing. Further plasmapheresis is anticipated for both patients.  83 
 84 
Discussion 85 
The two patients described here had severe bronchiectasis with significant morbidity, were 86 
refractory to conventional treatment, and unsuitable for lung transplantation. Novel therapies 87 
are desperately needed for such patients. Plasmapheresis restored serum-mediated killing of 88 
their infecting strain in vitro and correlated with rapid improvements in patient health and 89 
wellbeing; both patients reported greater independence and mobility than at any point in the 90 
previous two years, required fewer days in hospital and had a much reduced dependency on 91 
antibiotics.  92 
Plasmapheresis is a non-selective intervention removing protective antibodies against P. 93 
aeruginosa and other pathogens. We mitigated against this by infusing IVIg pooled from 94 
healthy individuals. Levels of inhibitory antibodies returned to pre-treatment levels within 95 
three months post-plasmapheresis, coinciding with increased symptoms and P. aeruginosa in 96 
sputum. Therefore, repeated plasmapheresis may be necessary to maintain benefit.  97 
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As plasmapheresis was used as salvage therapy, optimal treatment controls were not 98 
available. Thus, although striking, the results are preliminary. The outcome could be a 99 
placebo effect but given the supporting in vitro data and the repeated efficacy of treatment in 100 
separate patients this seems unlikely. The removal of other serum components by 101 
plasmapheresis may contribute to the resolution of infection. However, we are unaware of a 102 
factor other than immunoglobulin that could account for these findings that is i) found in 103 
plasma; ii) associated with bacterial killing; iii) has a long half-life and iv) accumulates so 104 
gradually after depletion by plasmapheresis. Other candidates such as CRP or components of 105 
complement are more readily replaceable. Measuring levels of inhibitory IgG2 in sputa post-106 
plasmapheresis would be relevant. The beneficial effects observed for these patients may be a 107 
consequence of administering IVIg. However, the potential role for IVIg alone was 108 
discounted by the clinical team reflecting the very high dilutional factors needed in vitro to 109 
suppress inhibitory antibodies. Suppressing blocking antibody production using rituximab 110 
was considered but the available evidence suggests that rituximab may increase respiratory 111 
infection rates in patients with bronchiectasis (9). Furthermore, the timescale for efficacy was 112 
felt to be months for rituximab therapy. To truly determine whether removal of anti-LPS 113 
IgG2 leads to health improvement, the ideal control would be to perform plasmapheresis on a 114 
patient with similar morbidity but no inhibitory antibody; this is ethically challenging. 115 
Ultimately, a randomized-blinded study of plasmapheresis in similar patient cohorts is 116 
essential to assess the efficacy and mechanism of action of this approach. 117 
In conclusion, we have described the first use of plasmapheresis to improve infection-related 118 
symptomatology. Its use in pre-transplant and transplant-ineligible patients is of particular 119 
interest.  Further multicentre studies of the prevalence of inhibitory antibody in 120 
bronchiectasis and other diseases with an infectious component will help us understand if 121 
plasmapheresis could be applied more widely.  122 
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Figure Legends 152 
Figure 1: Effect of plasmapheresis on patients with inhibitory antibodies. (A) Serum 153 
bactericidal assays using P. aeruginosa isolated from the sputum of PN1 (diamonds) or PN3 154 
(circles) with autologous patient serum, healthy control serum (HCS) or a 50:50 mix of 155 
patient serum and HCS; the patient serum was harvested before plasmapharesis. Negative 156 
values correspond with a decrease in viable P. aeruginosa compared with initial 157 
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concentration. (B) Box and whisker plot of mean of days spent in hospital (left axis) and CRP 158 
levels (right axis). Days spent in hospital calculated over 90 days for PN1 or PN3, 159 
recalculated monthly. CRP levels were measurements in the 3 months prior to plasmapheresis 160 
and the months after the treatment.  N indicates the number of CRP measurements used to 161 
make each box and whisker plot. 162 
Figure 2: Clinical data for patient’s pre and post-treatment. (A) Moving average of i.v. 163 
antibiotic use over 90 days, recalculated monthly for PN1 (diamonds) or PN3 (circles) pre 164 
and post plasmapheresis. (B) Tracking patient LPS IgG2 titers. The titer of IgG2 specific for 165 
the LPS of the patients’ cognate P. aeruginosa strain was measured by ELISA. ELISAs were 166 
done with purified LPS attached to a 96-well plate and dilutions of serum harvested from 167 
PN1 (diamonds) or PN3 (circles) at different dates. Patient sputum that cultured P. 168 
aeruginosa is indicated with an asterix (*). Points are coloured to indicate sera which was 169 
able (green) or unable (red) to kill the original patient isolate even when mixed 50:50 with 170 
HCS. The point of plasmapheresis is indicated by PP. 171 
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